0

What Americans Think About A Coronavirus Vaccine And Wearing Masks

Posted on

BROOKVILLE, N.Y., Oct. 6, 2020 /PRNewswire/ — Results of a breaking Long Island University Steven S. Hornstein Center for Policy, Polling and Analysis national poll on what Americans think about the coronavirus reveal that while there was uncertainty over taking a vaccine if it were available today, most respondents were confident that wearing masks reduces the spread of the virus.

Long Island University (PRNewsfoto/Long Island University)
Long Island University (PRNewsfoto/Long Island University)

MIXED CONFIDENCE IN POSSIBLE CORONAVIRUS VACCINE 
Americans were asked if they would agree to be vaccinated if an FDA approved coronavirus vaccine was available right now.  The result was a mixed response. Of the respondents, 38.2% said yes, 33.4% said no, and 28.4% said they didn’t know or gave no answer. Male respondents said yes at a higher rate (47%) than female respondents (31%).

THE MAJORITY OF AMERICANS (84%) ARE CONFIDENT THAT WEARING A MASK IN PUBLIC REDUCES THE SPREAD OF THE CORONAVIRUS
National poll results found that 84% of respondents said they believe that wearing a mask in public reduces the spread of the coronavirus, while 10% did not believe that wearing a mask in public makes a difference, and 6% said they were not sure.  Respondents with a household income above $100,000 showed confidence levels in masks at a higher rate (89%) than those with a household income below $100,000 (83%).

CONFIDENCE LEVEL OF WEARING MASKS IN PUBLIC TO REDUCE SPREAD OF CORONAVIRUS IS HIGHER IN NORTHEAST AND PACIFIC REGIONS; LOWER IN MIDWEST, SOUTH, AND MOUNTAIN REGIONS
Regional differences exist in Americans’ belief that wearing a mask in public reduces the spread of the coronavirus.  Respondents with the highest confidence level in wearing masks in public live in the Northeast (90%) and Pacific (89%) regions.  Respondents with lower confidence levels regarding wearing masks in public live in the Midwest (81%), South

0

Australian Treasurer Says Budget Assumes Virus Vaccine Next Year

Posted on

(Bloomberg) —



a row of computer equipment on a table: Glass vials move along a conveyor at the Gerresheimer AG medical glassware factory in Buende, Germany, on Tuesday, Aug. 11, 2020. Gerresheimer has built up capacity and most of its factories are operating around the clock as the company holds talks with pharma companies, working on a coronavirus vaccine.


© Bloomberg
Glass vials move along a conveyor at the Gerresheimer AG medical glassware factory in Buende, Germany, on Tuesday, Aug. 11, 2020. Gerresheimer has built up capacity and most of its factories are operating around the clock as the company holds talks with pharma companies, working on a coronavirus vaccine.

Australia’s budget forecasts will assume a coronavirus vaccine will be developed in the next year, Treasurer Josh Frydenberg says.

“The budget takes into account the possibility that is the case,” Frydenberg told Sky News Australia in a segment from an interview to be broadcast Monday”. “We have factored in those issues related to the vaccine and those will be available on budget night.”

Assuming a vaccine is available in 2021 will be a positive for the economic outlook, as it may signal a return to international travel and foreign tourist spending. Frydenberg is set to use his budget on Oct. 6 to ditch fiscal restraints and unveil a massive surge in spending to restart the economy after it fell into its first recession in almost 30 years.

“We have worked hard with international counterparts to secure the vaccine for Australia,” the treasurer said.

Australia has joined the COVAX Facility, part of international partnerships with the World Health Organization and other bodies aiming to ensure equitable access to safe and effective Covid-19 vaccines.

For more articles like this, please visit us at bloomberg.com

©2020 Bloomberg L.P.

Continue Reading

Source Article

0

Moderna, Pfizer & BioNTech, and AstraZeneca and the University of Oxford’s COVID-19 Vaccine Trials are Entering the Final Stage of Development

Posted on

DUBLIN, Oct. 2, 2020 /PRNewswire/ — ResearchAndMarkets.com published a new article on the vaccine industry “COVID-19 Vaccine Trials are Entering the Final Stage of Development”

Research and Markets Logo
Research and Markets Logo

Johnson & Johnson has begun final stage testing of its COVID-19 vaccine candidate. The company will trial the vaccine with 60,000 volunteers from around the world including participants from the US, South Africa, Brazil, Argentina, Columbia, and Chile. Johnson & Johnson’s vaccine joins candidates developed by Moderna, Pfizer and BioNTech, and AstraZeneca and the University of Oxford in beginning the final stage of development.

The company has committed to manufacturing a billion doses of the vaccine on a not for profit basis if proven effective. In contrast to other vaccine candidates that require at least two doses, J&J’s candidate requires just one dose. It also does not require freezing and can remain viable in its liquid form for several months. If the phase 3 trial is successful, both factors could have significant practical advantages for mass vaccination programs.

To see the full article and a list of related reports on the market, visit “COVID-19 Vaccine Trials are Entering the Final Stage of Development”

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/moderna-pfizer–biontech-and-astrazeneca-and-the-university-of-oxfords-covid-19-vaccine-trials-are-entering-the-final-stage-of-development-301144808.html

SOURCE Research and Markets

Source Article